Lung Cancer

Thirdhand Smoke: A New Concept Rising From Old Residue

By

Tori Rodriguez, MA, LPC, AHC

Publish Date November 28, 2018

The concept of thirdhand smoke was originally introduced in 1953, when rodent studies first demonstrated the carcinogenic effects of the residue from tobacco smoke.

Lung Cancer Imaging in Asymptomatic Patients: To Screen or Not to Screen?

By

Suzanne Bujara

Publish Date August 29, 2018

Although screening for lung cancer with low-dose computed tomography has demonstrated a reduction in mortality, some experts say the benefits do not outweigh the potential harms.

Exercise May Improve Quality of Life in Lung Cancer

By

Leah Lawrence

Publish Date February 16, 2018

Study examines increased physical activity may lower the risk for several cancers and may be beneficial for improving quality of life.

Cancer Survival Increasing in High-Income Countries

During the study period, progress in cancer control (increased survival, decreased mortality and incidence) was seen for stomach, colon, lung (in men), and ovarian cancer.

Factors Underlying Ethnic Differences in NSCLC Treatment Toxicity, Response

There are few clinical trials examining immune checkpoint inhibitor therapy in advanced NSCLC that enroll a high percentage of Asian patients.

Adding Adoptive Immunotherapy to Chemotherapy May Improve Survival in NSCLC

Autologous activated killer T cells and dendritic cells from regional lymph nodes were infused with or without chemotherapy in the adjuvant setting.

Artificial Intelligence Increases Clinical Trial Enrollment in Lung Cancer

IBM Watson Health’s Clinical Trials Matching (CTM) is an artificial intelligence system that can increase the efficiency of patient screening and recruitment into clinical trials.

Comparative Effectiveness, Safety of First-Line Chemotherapy Regimens in Advanced NSCLC

There are few observational studies examining patients with aNSCLC who have been treated with immune checkpoint inhibitor therapy.